Pfizer and BioNTech Announce Promising Results from Clinical Trials Evaluating mRNA Vaccine against COVID-19 and Influenza

Published: October 2023

On 27 October 2023, Pfizer and BioNTech report favorable outcomes from the early stage of their joint mRNA vaccine trials targeting both COVID-19 and influenza. The companies noted strong immune responses and safety profiles consistent with their COVID-19 vaccine in Phase I and II trials. They anticipate commencing a critical Phase III trial for these primary formulations in the near future. This mRNA vaccine has the potential to streamline immunization practices worldwide, offering the convenience of a single injection to mitigate the impact of two respiratory diseases for providers, patients, and healthcare systems.

According to Roots Analysis, the mRNA therapeutics and vaccine market is estimated to be worth $51 billion in 2022 and is expected to grow at steady rate during the forecast period.

For detailed insights about this domain, check out our report on mRNA Therapeutics and Vaccine Market or email sales@rootsanalysis.com

You may also be interested in the following titles:

MEDIA CITATIONS

With the wearable device market expected to provide a smart and straightforward drug delivery experience to patient populations worldwide..

Driven by the Growing Demand for Biologics, the Biopharmaceutical Contract Manufacturing Market is Expected to Grow at an Annualized Rate of 8.1%..

A new analysis by Roots Analysis has predicted that the antibody drug conjugates (ADC) market will be worth more than $15 billion by 2030, growing at a compound annual growth rate (CAGR) of over 20 percent due to their growing popularity and therapeu..

For kidneys, Roots Analysis, a medical-technology consultancy, reckons that should be possible in about six yearsâ€™ time. Livers, which have a natural tendency to regenerate anyway, should also arrive reasonably soon. Hearts, with their complex inte..

Roots Analysis predicts the gene therapy market as a whole to reach ~$11 bln by 2025..

Roots Analysis, a market research and consulting firm for the pharmaceutical industry, says that growth will add to the estimated â€œcurrent global contract pharmaceutical installed manufacturing capacity of 125 million liters [30.4 million U.S. gall..

There are few companies with the capability to commercially manufacture viral vectors; most of the 24 firms identified by Roots Analysis in a 2016 report are CDMOs...

Roots Analysis estimates there are over 500 gene therapy candidates in clinical development, with approximately 1,700 clinical studies underway around the world...

We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry

Pfizer and BioNTech Announce Promising Results from Clinical Trials Evaluating mRNA Vaccine against COVID-19 and Influenza

Novo Nordisk Invested EUR 2.1 Billion in a French Manufacturing Site to Meet Growing Demand for Diabetes and Obesity Therapies

Autism and Maternal Immune Activation: Groundbreaking Insights

Market Insights Reports

Indication Specific Reports

Who we are

Our Team

FAQ's

Pfizer and BioNTech Announce Promising Results from Clinical Trials Evaluating mRNA Vaccine against COVID-19 and Influenza

Novo Nordisk Invested EUR 2.1 Billion in a French Manufacturing Site to Meet Growing Demand for Diabetes and Obesity Therapies

Autism and Maternal Immune Activation: Groundbreaking Insights